Anjan Kumar Giri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anjan Kumar Giri has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Archismita Santra
Department Community Medicine Employees State Insurance-Post Graduate Institute of Medical Sciences and Research & Employees State Insurance Corporation Medical College and Hospital West Bengal India
1 shared publication - Arvind Kumar Shukla
All india institute of medical sciences raipur
1 shared publication - Dablu Lal Gupta
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Raipur, India
1 shared publication Dn Rao
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi - India
1 shared publicationEli Mohapatra
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh - India
1 shared publication- Jhasaketan Meher
ALL INDIA INSTITUTE OF MEDICAL SCIENCE
1 shared publication
Latest Publications
- Open Access
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 20-26
RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients
Introduction: It is unclear whether induced spike protein-specific antibodies due to infections with SARS-CoV-2 or to the prototypic Wuhan isolate-based vaccination can immune-react with the emerging variants of SARS-CoV-2. Aim/objectives: The main objective of the study was to measure the immunoreactivity of induced antibodies postvaccination with Covishield™ (ChAdOx1 nCoV-19 coronavirus vaccines) or infections with SARS-CoV-2 by using selected peptides of the spike protein of wild type and variants of SARS-CoV-2. Methodology: Thirty patients who had recovered from SARS-CoV-2 infections and 30 individuals vaccinated with both doses of Covishield™ were recruited for the study. Venous blood samples (5 mL) were collected at a single time point from patients within 3-4 weeks of recovery from SARS-CoV-2 infections or receiving both doses of Covishield™ vaccines. The serum levels of total immunoglobulin were measured in both study groups. A total of 12 peptides of 10 to 24 amino acids length spanning to the receptor-binding domain (RBD) of wild type of SARS-CoV-2 and their variants were synthesized. The serum levels of immune-reactive antibodies were measured using these peptides. Results: The serum levels of total antibodies were found to be significantly (p<0.001) higher in the vaccinated individuals as compared to COVID-19 recovered patients. Our study reported that the mutations in the RBD at the residues K417, E484, and N501 have been associated with reduced immunoreactivity with anti-sera of vaccinated people and COVID-19 recovered patients. Conclusion: The amino acid substitutions at the RBD of SARS-CoV-2 have been associated with a higher potential to escape the humoral immune response.
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 20-26
Open AccessRBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients
Introduction: It is unclear whether induced spike protein-specific antibodies due to infections with SARS-CoV-2 or to the prototypic Wuhan isolate-based vaccination can immune-react with the emerging variants of SARS-CoV-2. Aim/objectives: The main objective of the study was to measure the immunoreactivity of induced antibodies postvaccination with Covishield™ (ChAdOx1 nCoV-19 coronavirus vaccines) or infections with SARS-CoV-2 by using selected peptides of the spike protein of wild type and variants of SARS-CoV-2. Methodology: Thirty patients who had recovered from SARS-CoV-2 infections and 30 individuals vaccinated with both doses of Covishield™ were recruited for the study. Venous blood samples (5 mL) were collected at a single time point from patients within 3-4 weeks of recovery from SARS-CoV-2 infections or receiving both doses of Covishield™ vaccines. The serum levels of total immunoglobulin were measured in both study groups. A total of 12 peptides of 10 to 24 amino acids length spanning to the receptor-binding domain (RBD) of wild type of SARS-CoV-2 and their variants were synthesized. The serum levels of immune-reactive antibodies were measured using these peptides. Results: The serum levels of total antibodies were found to be significantly (p<0.001) higher in the vaccinated individuals as compared to COVID-19 recovered patients. Our study reported that the mutations in the RBD at the residues K417, E484, and N501 have been associated with reduced immunoreactivity with anti-sera of vaccinated people and COVID-19 recovered patients. Conclusion: The amino acid substitutions at the RBD of SARS-CoV-2 have been associated with a higher potential to escape the humoral immune response.
- Open Access
- 30 September 2023
- Published by Indian Association of Preventive and Social Medicine in Indian Journal of Community Health
- Vol. 35 (3) , 258-263
Rabies elimination policy guidelines: Where do we stand?
Introduction: Rabies is one of the Neglected Tropical diseases. India accounts for 35% of rabies-related human deaths globally. Despite effective preventive and control strategies, India hasn't been able to eliminate rabies. Methodology: A narrative review was done by comparing various policies and programmes related to rabies control and elimination in India and other countries, and the gaps persisting in the Indian guidelines and its implementation were assessed. Results: There are multiple gaps in the Indian programme implementation ranging from multiple stockouts of vaccines, unavailability of rabies immunoglobulin, and lack of a robust surveillance system to lack of refreshing training of the health staff. Recommendations: For effective implementation, the population should have increased awareness, with increased production and an effective supply chain of vaccines and immunoglobulins. There should also be a robust surveillance system with periodic refresher training of the health staff.
- 30 September 2023
- Published by Indian Association of Preventive and Social Medicine in Indian Journal of Community Health
- Vol. 35 (3) , 258-263
Open AccessRabies elimination policy guidelines: Where do we stand?
Introduction: Rabies is one of the Neglected Tropical diseases. India accounts for 35% of rabies-related human deaths globally. Despite effective preventive and control strategies, India hasn't been able to eliminate rabies. Methodology: A narrative review was done by comparing various policies and programmes related to rabies control and elimination in India and other countries, and the gaps persisting in the Indian guidelines and its implementation were assessed. Results: There are multiple gaps in the Indian programme implementation ranging from multiple stockouts of vaccines, unavailability of rabies immunoglobulin, and lack of a robust surveillance system to lack of refreshing training of the health staff. Recommendations: For effective implementation, the population should have increased awareness, with increased production and an effective supply chain of vaccines and immunoglobulins. There should also be a robust surveillance system with periodic refresher training of the health staff.